News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The new website is awesome, full of the entire story and details.
https://exousiapro.com/why-exosomes/
Super tiny float $MAJI is now a Brain Cancer, Glioblastoma cancer, Next-Gen Drug-Biotech
$MAJI – Attention shareholders, we are pleased to announce that Dr. Hausman has submitted the revised Orphan Drug Application for Glioblastoma with the additional information requested. The additional information was provided by the scientific team at the University of Central… pic.twitter.com/SWFihY3Snt
— Exousia Pro (@Exousia_Pro) June 17, 2025
Load and Hold..................
Gotta love shorts filling my bags with cheap shares of $MAJI
Can't fix stupid, but I can pick their pockets
It is my Understanding that GBM stem cells (Maybe other cancer stem cells as well) are why cancers come back.
The MAJI Exosomes are expected to enable 100% elimination of the cancer stem cells.
BIXT's Prolectin-M Galectin-3 Inhibitor also has a cancer application, and MS is an officer of both companies, BIXT and MAJI.
I am curious to see it the MAJI exosomes can be used to expand the reach and delivery of BIXT's Prolectin-M Galectin-3 Inhibitor through the blood brain barrier (If needed)
As I have been preaching for ages,
"Answer only important if ask right question"
AI Overview
Learn more
Galectin-3 plays a significant role in the characteristics and behavior of cancer stem cells (CSCs), which are a subset of tumor cells responsible for tumor initiation, recurrence, and metastasis. Specifically, Galectin-3 influences CSC traits such as sphere formation, drug resistance, and invasion, and it may be involved in regulating CSC-associated signaling pathways.
Here's a more detailed look at how Galectin-3 affects CSCs:
Sphere Formation: Galectin-3 promotes the formation of cancerspheres, which are a 3D culture model that mimics the stem cell-like phenotype of CSCs. This indicates that Galectin-3 supports the maintenance of stem cell properties within cancer cells.
Drug Resistance: Galectin-3 is implicated in drug resistance, a key characteristic of CSCs. By protecting CSCs from chemotherapy-induced cell death, Galectin-3 may contribute to the persistence and recurrence of tumors.
Invasion and Metastasis: Galectin-3 regulates the invasion and migration of cancer cells, including those with stem cell-like characteristics. This suggests that Galectin-3 may also contribute to the metastasis of tumors by promoting the spread of CSCs to distant sites.
Signaling Pathways: Galectin-3 may influence signaling pathways involved in CSC-associated phenotypes. For example, it can modulate the Wnt/ß-catenin pathway, which is known to play a role in cancer stemness and progression.
Potential Therapeutic Target: Because of its involvement in CSC characteristics and drug resistance, Galectin-3 is being explored as a potential therapeutic target in cancer treatment. Targeting Galectin-3 could potentially disrupt the stem cell-like properties of tumors and enhance the effectiveness of chemotherapy
That connects the dots of $BIXT With $MAJI in a huge way. Add $MRK and the cancer drugs, and $MAJI and $BIXT expected ability to triple the cure rate of $MRK cancer drugs, and you have monster JV, deals and upside to look forward to for all these stocks.
If some of you got lost in the science of that paper, the take home message is that NANOG and OCT4 are the bad guys. Imagine. NANOG is like the cell wall (castle moat/defenders) keeping the chemotherapy (TMZ in this case) from getting into the cancer cell (castle). They resist the drug (TMZ). So key sentence: When the GBM cells were treated with shRNA targeting NANOG or OCT4 in combination with TMZ, the level of cell death was significantly higher compared to that of the TMZ treatment alone, suggesting that the inhibition of NANOG or OCT4 increased the efficacy of TMZ. So when you send TMZ alone to the castle, only about 25% of it gets through the defenses. When you load TMZ into those tiny nano-sized $MAJI exosomes, most of it gets through the defenses and the kill rate goes way up. See chart. The black bars are cells killed with TMZ alone (the way people with GBM are treated now). The red bars are cells killed with TMZ + shRNA in exosomes. Impressive.
Great place to catch up on the news of this new company and to watch for new news that is pending.
https://finance.yahoo.com/quote/MAJI/news/
$MAJI is moving fast into the Exozone Oncology field. Glioplastoma Brain Cancer. , trial for boosting the $MERC Cancer drug performance.
**Dr. Marvin Hausman is joining Exousia Pro as a Consultant and will host a weekly series.**
ORLANDO, FL / ACCESS Newswire / April 30, 2025 / MARIJUANA INC. (OTCPINK:**$MAJI**), dba Exousia Pro, Inc., **a clinical-stage biotech company utilizing exosomes in therapies helpful in the treatment of cancer and other diseases, is launching a weekly web series titled "Ask Dr. Hausman."**
Our chief science officer, Dr. Marvin Hausman, will join Exousia Pro as a consultant; his contract is being finalized now. **Dr. Hausman was instrumental in creating Exousia AI **and **establishing the Glioblastoma study with UCF, and will assist Exousia Pro in advancing therapies using our plant-based exosomes. Exousia Pro will launch a new web series, "Ask Dr. Hausman." Shareholders will be able to email questions that Dr. Hausman will answer weekly. Dr. Hausman will also share updates on various studies conducted, our FDA submissions, and future IND trials.**
Matt Dwyer, our President, stated, "Exousia Pro is very fortunate to have Dr. Hausman working with us. **His rolodex of scientific and financial professionals in the biotech world is priceless. We believe that Dr. Hausman can open doors for Exousia Pro that we could never do.** I met Marvin about 1 year ago and have established a strong relationship with him, and I look forward to working closely with him in advancing Exousia Pro."
About Us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
https://www.exousiapro.com
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/exousia-pro-will-launch-a-web-series-with-our-new-consultant-1021683
I suspect most people do not get that the test MAJI ran was using the MAJI Exosomes to deliver a $MERC cancer drug to the Glioblastoma brain cancer cells, and the Placebo was just the $MERC Cancer drug.
$MERK makes billions on only partly effective Cancer drugs.
If the $MAJI results, double, or triple the cure rate we land on the Moon immediately, before $MERC makes a deal.
Once $MERC Makes a deal we leave the galaxy.
Huge news out on $MAJI today
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/exousia-pro-finishes-preclinical-trial-for-glioblastoma-ahead-of-sche-1021225
https://www.otcmarkets.com/stock/MAJI/news/Exousia-Pro-Finishes-Preclinical-Trial-for-Glioblastoma-Ahead-of-Schedule---Bolstering-Orphan-Drug-Application?id=475208
Nano Float and OS, and could end up with a deal with $MERC $$$$$$$$$$$
Under the radar news. Brain cancer #Glioblastoma
- Rigorous humanized mouse model enhances credibility and translatability of results
- Key preclinical data to support FDA Orphan Drug Application
- In vitro success signals potential for exosome-based therapy breakthrough
ORLANDO, FL / ACCESS Newswire / April 29, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in therapies helpful in the treatment of cancer and other diseases, is pleased to announce the early completion of its preclinical trial for glioblastoma, a highly aggressive brain cancer. This milestone strengthens the company's FDA Orphan Drug Application and positions Exousia Pro to become a leader in innovative cancer treatments.
Nearly 90% of glioblastoma preclinical studies rely on genetically engineered or chemically induced mouse models, limiting their relevance to human disease. Exousia Pro set a higher standard by employing a sophisticated humanized mouse model. By implanting surgically removed human glioblastoma tumor cells into immunodeficient mice, we ensured a clinically relevant evaluation of therapeutic efficacy. This approach significantly enhances the credibility of our results. While more costly, this rigorous approach ensures robust, translatable results, as the therapy's efficacy is tested without interference from the mouse's immune system.
The trial involved 32 mice implanted with glioblastoma patient-derived tumor cells into the brain. After a 14-day tumor establishment period, the mice were randomized into four cohorts: control, conventional temozolomide (TMZ) treatment alone, exosome treatment alone, and a TMZ-exosome combination therapy. Following seven days of treatment, evaluations focused on key metrics, including tumor size, and body weight changes to assess treatment efficacy and overall mouse health. Tumor size reduction will be critical in supporting the company's FDA Orphan Drug Application, while detailed brain slices immunohistochemical analyses are expected to reveal the underlying therapeutic effects. A comprehensive report is expected by mid-to-late May 2025.
"This preclinical trial could alter the trajectory of exosomal-based therapies which has seen relatively low adoption due to production and manufacturing inefficiencies," said Mike Sheikh, CEO of Exousia Pro. "We can target and load the exosome in a singular process whereby the cell does all the work for us. Our in vitro studies demonstrated that our exosomal therapy, combined with minimal chemotherapy, significantly enhances the elimination of cancer stem cells-the primary barrier to effective glioblastoma therapy. If our preclinical results validate or exceed these findings, Exousia Pro could achieve global recognition and transform the standard of care for glioblastoma patients.
The company anticipates key positive preclinical data for submission to the FDA in order to advance the Orphan Drug Application, potentially unlocking significant regulatory and financial benefits.
News Flash "conventional temozolomide (TMZ) treatment alone, exosome treatment alone, and a TMZ-exosome combination therapy." Is Made by $MERC
Improving the cancer rate of a $MERC drug will be a Gold mine for $MAJI shareholders
A published paper shows NANOG Expression was almost 100% effective at eradicating tumor cells
ORLANDO, FL / ACCESS Newswire / April 21, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc. , a clinical-stage biotech company utilizing exosomes in the treatment of cancer and other diseases, is pleased to share published information about the therapy being used in our current Glioblastoma ("GBM") study.
Dr. Marvin Hausman , our Chief Science Officer, revealed Thursday live on a Spaces interview that a paper had been published showing that the NANOG Expression therapy reduced the resistance of the Cancer stem cells in Glioblastoma. In fact, the paper goes on to reveal that when temozolomide ("TMS") was used on its own at its highest concentration, less than 20% of the GBM cells were killed. When the GBM cells were treated with shRNA targeting NANOG or OCT4 in combination with TMZ, the level of cell death was significantly higher compared to that of the TMZ treatment alone, suggesting that the inhibition of NANOG or OCT4 increased the efficacy of TMZ.
The full paper may be read here: https://pmc.ncbi.nlm.nih.gov/articles/PMC10297980/
Matt Dwyer , our President, stated, "I was listening to the Spaces interview and couldn't believe what I was hearing. I had no clue this information existed. I know the current study and its findings, but this was mind-blowing. I suggest everyone go listen to Dr. Hausman and pay attention to the excitement in his voice as he discusses the ongoing study."
|
Followers
|
485
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
74226
|
|
Created
|
12/27/10
|
Type
|
Free
|
| Moderators i_like_bb_stock | |||
AI
